Author

Philip Smith

EFFICACY AND SAFETY OF ELECTIVE SWITCHING OF INFLAMMATORY BOWEL DISEASE PATIENTS FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB: A MULTI-CENTRE COHORT STUDY
EFFICACY AND SAFETY OF ELECTIVE SWITCHING OF INFLAMMATORY BOWEL DISEASE PATIENTS FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB: A MULTI-CENTRE COHORT STUDY

Philip Smith  et al.

EFFICACY OF SUBCUTANEOUS INFLIXIMAB IN PERIANAL CROHN’S DISEASE
EFFICACY OF SUBCUTANEOUS INFLIXIMAB IN PERIANAL CROHN’S DISEASE

Philip Smith  et al.

EFFICACY AND SAFETY OF ELECTIVE SWITCHING OF INFLAMMATORY BOWEL DISEASE PATIENTS FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB: A MULTI-CENTRE COHORT STUDY
EFFICACY AND SAFETY OF ELECTIVE SWITCHING OF INFLAMMATORY BOWEL DISEASE PATIENTS FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB: A MULTI-CENTRE COHORT STUDY

EFFICACY OF SUBCUTANEOUS INFLIXIMAB IN PERIANAL CROHN'S DISEASE
EFFICACY OF SUBCUTANEOUS INFLIXIMAB IN PERIANAL CROHN'S DISEASE

TREATMENT DISCONTINUATION DUE TO LACK OF EFFICACY DURING MAINTENANCE TREATMENT WITH INFLIXIMAB OR VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE: A COMPARATIVE ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
TREATMENT DISCONTINUATION DUE TO LACK OF EFFICACY DURING MAINTENANCE TREATMENT WITH INFLIXIMAB OR VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE: A COMPARATIVE ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Philip Smith  et al.

Item 1 - 5 / 5
1